Amidst the currently expansive healthcare space, encompassing numerous verticals, HLA typing for transplant market has profoundly inked a rather progressive growth path, subject to the escalating requirement of organ transplantation which includes both cellular and humoral immune responses. As per clinical research, at least 6 HLA (Human Leukocyte Antigens) of the donor need to be matched with the organ receiver, since the success of stem cell transplantation is mainly dependent on the accuracy level of HLA matching among donors and receivers – higher the accuracy, lesser the complication risk. Having identified this potential factor and considered the benefits of human leukocyte antigens typing for transplants, many of the research institutes and diagnostics centers have been deploying this technique on large scale, thereby providing a positive impetus to HLA typing for transplant industry. It is prudent to state that the increasing use of advanced technologies across various healthcare facilities will help to identify and correlate the best possible transplant outcomes, further spurring HLA typing for transplant industry trends. Indeed, the growing acceptance of next-generation sequencing for organ transplantation will be one of the pivotal driving forces of HLA typing for transplant market size in the ensuing years.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/1653
Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
1. Abbott Laboratories
2. Bio-Rad Laboratories
3. Bio-Reference Laboratories
4. CareDx, Inc
6. Illumina Inc.
7. Immucor Inc.
8. Inno-train Diagnostik
9. Luminex Corporation
- Massachusetts Eye and Ear
At present, HLA typing for transplant industry is characterized by many research organizations and technology companies developing countable numbers of transplantation techniques and medicinal kits. In 2017 for instance, the Australian molecular diagnostic company, TBG Biotechnology, received the approval for its HLA genotyping kits for HCT (hematopoietic cell transplantation) from the China Food and Drug Administration (CFDA). After the approval, TBG apparently even collaborated with hematopoietic cell transplantation service providers and laboratory distributors, expanding the scope of HLA typing for transplant market. As per estimates, China is one of the largest consumers of allogeneic HCT market, therefore, increasing the rate of approval for HLA typing laboratories from CFDA is undeniably bound to stimulate China HLA typing transplant industry outlook.
Browse Report Summary @ https://www.gminsights.com/industry-analysis/hla-typing-for-transplant-market
In order to augment the revenue graph of HLA typing in transplant industry, renowned players have been focusing on technology development, discovery, and commercialization of high-value diagnostic methodologies for organ transplantation, on the grounds of which, companies are adopting advanced software-based technologies. For instance, last year, CareDx, Inc. acquired Assign™ SBT analysis software and Conexio SBT Resolver™ from Illumina, Inc. for improving high-resolution HLA typing. This technology apparently, has set a new benchmark ahead of several other biggies in HLA typing for transplant market with product innovation and high-quality HLA (Human Leukocyte Antigens) typing. This acquisition also helped CareDx to build its transplant business through the launch of new products and the commercialization of its existing portfolio. With firms such as CareDx and Illumina signing deals related to transplantation technology, next-generation sequencing system based HLA typing has gained remarkable momentum in recent years. In fact, after evaluating HLA typing results associated with next-generation sequencing based, one of the leading giants in NGS HLA typing transplantation and sequencing-based typing, based in Netherlands, GenDx signed an agreement with one of the well-known behemoths in HLA typing for transplant market, Thermo Fisher Scientific, to provide Ion PGM and NGSengine software to customers. The aforementioned detail validates that heavy investments in R&D activities to enhance existing technology will indeed fuel HLA typing for transplant industry share.
Organ transplant methods have indeed aided millions of patients, however, in order to increase the availability of organs, most giants in HLA typing for transplant market have been making heavy investments to research on more accurate and precise methodologies that would further promote the acceptance of transplantation technique across the globe. In consequence, this would have a profound impact on the revenue graph of HLA typing for transplant industry, slated to register a CAGR of 10% over 2017-2024.